FABP Biotech

📍 Rio de Janeiro, Brazil🗓 Founded 2020👥 10 employees💰 Last funded Sep 2022
Biotechnology Research🌐 fabpbiotech.com.br
Website LinkedIn
FABP Biotech is a spin-off of the Oswaldo Cruz Foundation created under the regulatory framework of the Brazilian Technological Innovation Law to develop anti-helminth vaccines for animal use. FABP Biotech holds the exclusive licensing of patents and rights for the final development, registration, and commercialization of vaccines and veterinary products based on Sm14. The Sm14 Fatty Acid Binding Protein elicits a robust immune response in animals with helminth infections, making it a promising target for a multivalent vaccine. A range of globally filed and granted patents describe the use of Sm14 in vaccines, and researchers continue to explore its potential as a prophylactic and therapeutic tool. FABP Biotech currently explores the Sm14 technology in two ways: 1. LIVAC ® — Sm14 vaccine to prevent fasciolosis in livestock (cattle, goats, and sheep). 2. Sm14PET — Sm14 vaccine for worms that affect pets, such as heartworm.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Brazil
1
Frequently asked questions
Who invested in FABP Biotech?
FABP Biotech has 1 investors on record on gritt.io, including 1 early-stage backers.
When did FABP Biotech last raise funding?
The most recent investment in FABP Biotech recorded on gritt.io was in September 2022.
When was FABP Biotech founded?
FABP Biotech was founded in 2020.
What industry is FABP Biotech in?
FABP Biotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is FABP Biotech based?
FABP Biotech is headquartered in Rio de Janeiro, Brazil.